U.K. pharma giant agrees to sell its small molecule antibiotics business to Pfizer of the U.S. » Read More
By: Dan Mangan
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent. » Read More
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Patients missing out on their medication or taking the wrong dose costs the U.S. health care system $290 billion each year, according to a new report.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
Barbara Ryan, Partner at Barbra Ryan Advisors, discusses the biotech and pharma space as rumors fly on a takeover deal for Biogen.
Geoff Porges, Leerink Partners Managing Director & Senior Biotech Analyst, discusses the news that Biogen is a possible takeover target for the likes of Merck and Allergan.
Sources say Allergan is unlikely to pursue Biogen deal. CNBC's Meg Tirrell reports the details. The "Fast Money" traders weigh in.
The "Fast Money" traders discuss their views on Biogen.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
CNBC's Meg Tirrell reports the latest of what Pfizer CEO Ian Read has to say on biotech valuations, the election and more. The “Fast Money Halftime Report” traders and Stephanie Link, TIAA Global Asset Management, weigh in.
Pfizer's results were driven by lower taxes and demand for new medicines, but it stuck to its previous sales and profit forecasts for the full year.
Theranos CEO Elizabeth Holmes tries to convince experts her company's controversial blood testing technology actually works at the AACC. CNBC's Meg Tirrell reports.
Jim Cramer reviewed the recent bullish actions taken by Tesla and Uber, and says it could mean big things for historically difficult August.
Discussing implied earnings moves in big pharma, including Pfizer, Allergan and more with CNBC contributor Mike Khouw. The "Fast Money" traders weigh in.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
Theranos CEO Elizabeth Holmes pledged on Monday to increase transparency regarding its testing methods.
Most claims of opioid dependence involved adults between the ages of 19 and 35.
Get the best of CNBC in your inbox